Cargando…
Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression
Despite decades of research efforts and multiple clinical trials aimed at discovering efficacious disease-modifying osteoarthritis (OA) drugs (DMOAD), we still do not have a drug that shows convincing scientific evidence to be approved as an effective DMOAD. It has been suggested these DMOAD clinica...
Autores principales: | Guermazi, Ali, Roemer, Frank W., Crema, Michel D., Jarraya, Mohamed, Mobasheri, Ali, Hayashi, Daichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103249/ https://www.ncbi.nlm.nih.gov/pubmed/37063459 http://dx.doi.org/10.1177/1759720X231165558 |
Ejemplares similares
-
Role of imaging for eligibility and safety of a-NGF clinical trials
por: Roemer, Frank W., et al.
Publicado: (2023) -
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
por: Oo, Win Min, et al.
Publicado: (2022) -
Latest advancements in imaging techniques in OA
por: Hayashi, Daichi, et al.
Publicado: (2022) -
The current state of the osteoarthritis drug development pipeline: a
comprehensive narrative review of the present challenges and future
opportunities
por: Kim, Heungdeok, et al.
Publicado: (2022) -
Early knee OA definition–what do we know at this stage? An imaging perspective
por: Li, Xiaojuan, et al.
Publicado: (2023)